- |||||||||| inecalcitol (TX-522) / Hybrigenics
Journal: Biological evaluation of combinations of tyrosine kinase inhibitors with Inecalcitol as novel treatments for human chronic myeloid leukemia. (Pubmed Central) - Feb 1, 2024
Furthermore, the combination treatments showed synergistic interaction between the antileukemic drugs and Inecalcitol, with combination indices (CI) < 1. The study demonstrated that the human chronic myeloid leukemia K-562 cells were subjected to a synergistic growth inhibitory impact when antileukemic drugs (Imatinib or Dasatinib) were combined with Inecalcitol, therefore, it is recommended that these combinations be viewed as promising novel antileukemic medications and used in place of individual medications with lower dosages and negligible side effects in the treatment of CML.
- |||||||||| Ibrance (palbociclib) / Pfizer, inecalcitol (TX-522) / Hybrigenics
Preclinical, Journal: The Combination of the CDK4/6 Inhibitor, Palbociclib, With the Vitamin D Analog, Inecalcitol, Has Potent In Vitro and In Vivo Anticancer Effects in Hormone-Sensitive Breast Cancer, But Has a More Limited Effect in Triple-Negative Breast Cancer. (Pubmed Central) - Jul 6, 2022
Furthermore, in vivo validation in a MCF7 cell line-derived xenograft mouse model decreased tumor growth and cell cycle progression after combination therapy, but not in a TNBC BT20 cell line-derived xenograft model. In conclusion, we show that addition of a potent vitamin D analog to selective CDK4/6 inhibitor treatment results in increased antiproliferative effects in ER BC both in vitro and in vivo.
|
